Amgen (AMGN) PT Raised to $280 at Jefferies

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/13/2026

1. WDAY
2. AAPL
3. JNJ
4. META
5. NRIX
6. SUNS
7. AMAT
8. SPY
9. SNDX
10. CRDO

Go back to Amgen (AMGN) PT Raised to $280 at Jefferies

Amgen (AMGN) PT Raised to $250 at Wells Fargo

February 9, 2022 6:36 AM EST

Wells Fargo analyst Mohit Bansal raised the price target on Amgen (NASDAQ: AMGN) to $250.00 (from $210.00) while maintaining a Equal Weight rating.... More

Amgen (AMGN) PT Raised to $285 at Oppenheimer

February 9, 2022 4:53 AM EST

Oppenheimer analyst Jay Olson raised the price target on Amgen (NASDAQ: AMGN) to $285.00 (from $272.00) while maintaining a Outperform rating.... More

Amgen (AMGN) PT Raised to $233 at Barclays

February 9, 2022 4:47 AM EST

Barclays analyst Carter Gould raised the price target on Amgen (NASDAQ: AMGN) to $233.00 (from $228.00) while maintaining a Equalweight rating.... More

Amgen (AMGN) PT Raised to $238 at Morgan Stanley

February 9, 2022 1:09 AM EST

Morgan Stanley analyst Matthew Harrison raised the price target on Amgen (NASDAQ: AMGN) to $238.00 (from $235.00) while maintaining a Equalweight rating.... More

Amgen to buy back $6 billion in shares this qtr, provides long-term profit forecast

February 8, 2022 10:48 AM EST

By Deena Beasley and Leroy Leo

(Reuters) -Amgen Inc said on Tuesday it would buy back up to $6 billion of its shares in the first quarter and forecast profit to more than double by 2030 on strong sales of its oncology drugs, biosimilars and other important products.

Shares of the U.S. biotechnology company jumped 8% to $241.37.

Amgen also said it expects to deliver mid-single-digit revenue growth through the end of the decade, driven by treatments such as cholesterol drug Repatha, psoriasis medicine Otezla and a pipeline of innovative products in development.

... More

Amgen (AMGN) Outlines Growth Strategy Through 2030

February 8, 2022 10:22 AM EST

Amgen (NASDAQ: AMGN) today outlined its growth strategy through 2030, a period during which the Company expects to deliver attractive financial performance by serving many more patients globally than it does today, both with its current portfolio of marketed medicines and with the numerous new medicines it is advancing through its pipeline.

"Our strategy of delivering innovative medicines to address significant areas of unmet need has served us well over the past decade and remains our North Star moving forward in this exciting era of transformation for our industry," said Robert A.... More